Return of results has been examined in a wide range of studies of new genomic technologies, such as whole genome sequencing, microarrays, and exome sequencing. These new technologies have been utilized in conditions as diverse as breast cancer, Miller’s syndrome, and coronary artery disease. A panel [G-1] examining these emerging analytical technologies addressed patients’ and providers’ perceptions about the significance of information derived from novel technologies for a range of research subjects: asymptomatic individuals, families with extremely rare disorders, and individuals testing negative for well-proven genetic associations.
